LLY vs. META: Eli Lilly vs. Meta Platforms Stock Comparison
How do Eli Lilly (LLY) and Meta Platforms (META) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Eli Lilly (LLY) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Meta Platforms (META) belongs to Communication Services (Media & Entertainment) — their GICS classifications point to very different parts of the market.
| Profile Item | LLY | META |
|---|---|---|
| Name | Eli Lilly and Company | Meta Platforms Inc Class A |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Communication Services |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Media & Entertainment |
| GICS Industry | Pharmaceuticals | Interactive Media & Services |
| GICS Sub-Industry | Pharmaceuticals | Interactive Media & Services |
| Market Capitalization | 1,057.35 billion USD | 1,508.38 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | June 1, 1972 | May 18, 2012 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | LLY | META |
|---|---|---|
| Total Return (1Y) | 86.33% | -22.02% |
| Total Return (3Y, Annualized) | 38.69% | 23.57% |
| Total Return (5Y, Annualized) | 36.38% | 10.44% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | LLY | META |
|---|---|---|
| Volatility (1Y, Annualized) | 35.74% | 38.34% |
| Beta (5Y) | 0.50 | 1.25 |
| Max Drawdown (5Y) | -34.48% | -76.74% |
| Avg. Volume (3M) | 3.06M | 18.00M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | LLY | META |
|---|---|---|
| Sharpe Ratio (1Y) | 2.30 | -0.68 |
| Sortino Ratio (1Y) | 4.03 | -0.95 |
Profitability
ROE (TTM)
Both Eli Lilly (LLY) at 102.29% and Meta Platforms (META) at 29.85% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
102.29%
- LLY
- 102.29%
- Max
- 102.29%
- Q3
- 2.88%
- Median
- -33.17%
- Q1
- -64.41%
- Min
- -157.61%
META
Media & Entertainment industry group
29.85%
- Max
- 48.68%
- META
- 29.85%
- Q3
- 16.74%
- Median
- 6.46%
- Q1
- -5.13%
- Min
- -37.13%
Net Margin (TTM)
Eli Lilly (LLY) at 33.53% keeps the most of each sales dollar — above its industry’s net margin range — and Meta Platforms (META) at 29.84% also retains a top-quartile share.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.53%
- LLY
- 33.53%
- Max
- 11.21%
- Q3
- 2.65%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -13.58%
META
Media & Entertainment industry group
29.84%
- Max
- 30.77%
- META
- 29.84%
- Q3
- 9.84%
- Median
- 3.58%
- Q1
- -4.22%
- Min
- -24.17%
Operating Margin (TTM)
Both Eli Lilly (LLY) at 54.22% and Meta Platforms (META) at 34.83% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
54.22%
- Max
- 94.41%
- LLY
- 54.22%
- Q3
- 8.92%
- Median
- 0.00%
- Q1
- -119.39%
- Min
- -309.54%
META
Media & Entertainment industry group
34.83%
- Max
- 41.37%
- META
- 34.83%
- Q3
- 17.93%
- Median
- 9.02%
- Q1
- -1.89%
- Min
- -27.39%
Profitability Metrics
| Metric | LLY | META |
|---|---|---|
| ROE (TTM) | 102.29% | 29.85% |
| ROA (TTM) | 20.36% | 14.59% |
| Net Margin (TTM) | 33.53% | 29.84% |
| Operating Margin (TTM) | 54.22% | 34.83% |
| Gross Margin (TTM) | 83.40% | 81.75% |
Growth
Revenue Growth
Meta Platforms (META) at 22.17% sits in the top revenue growth quartile, while Eli Lilly (LLY) at 44.70% is closer to the peer norm — faster top-line expansion for META.
EPS Growth
Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Meta Platforms (META) at -1.55% is closer to the peer norm — faster per-share earnings growth for LLY.
Growth Metrics
| Metric | LLY | META |
|---|---|---|
| Revenue Growth (YoY) | 44.70% | 22.17% |
| Revenue Growth (3Y CAGR) | 31.69% | 19.89% |
| EPS Growth (YoY) | 95.99% | -1.55% |
| EPS Growth (3Y CAGR) | 51.71% | 39.84% |
Financial Strength
Current Ratio (MRQ)
Meta Platforms (META) at 2.23 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.36 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.36
- Max
- 26.16
- Q3
- 12.25
- Median
- 5.88
- Q1
- 2.81
- LLY
- 1.36
- Min
- 0.55
META
Media & Entertainment industry group
2.23
- Max
- 4.86
- Q3
- 2.72
- META
- 2.23
- Median
- 1.56
- Q1
- 0.87
- Min
- 0.09
Debt / Equity (MRQ)
Meta Platforms (META) at 0.43 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.62 uses more debt funding than most peers.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.62
- Max
- 1.64
- LLY
- 1.62
- Q3
- 0.68
- Median
- 0.16
- Q1
- 0.02
- Min
- 0.00
META
Media & Entertainment industry group
0.43
- Max
- 2.58
- Q3
- 1.26
- Median
- 0.52
- META
- 0.43
- Q1
- 0.17
- Min
- 0.00
Financial Strength Metrics
| Metric | LLY | META |
|---|---|---|
| Current Ratio (MRQ) | 1.36 | 2.23 |
| Debt / Equity (MRQ) | 1.62 | 0.43 |
| Net Debt / EBITDA | 1.10 | 0.20 |
Dividends
Dividend Yield (TTM)
Both Eli Lilly (LLY) at 0.54% and Meta Platforms (META) at 0.36% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.54%
- LLY
- 0.54%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
META
Media & Entertainment industry group
0.36%
- META
- 0.36%
- Max
- 0.24%
- Q3
- 0.12%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Meta Platforms (META) at 7.91% keeps its payout in the industry’s typical band, while Eli Lilly (LLY) at 21.69% pays out more than any of its peers — the most stretched cover in its group.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.69%
- LLY
- 21.69%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
META
Media & Entertainment industry group
7.91%
- Max
- 34.19%
- Q3
- 14.58%
- META
- 7.91%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | LLY | META |
|---|---|---|
| Dividend Yield (TTM) | 0.54% | 0.36% |
| Dividend Payout Ratio (TTM) | 21.69% | 7.91% |
Valuation
P/E Ratio (TTM)
Both Eli Lilly (LLY) at 40.00 and Meta Platforms (META) at 22.23 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.00
- Max
- 84.14
- Q3
- 43.16
- LLY
- 40.00
- Median
- 28.60
- Q1
- 15.80
- Min
- 2.32
META
Media & Entertainment industry group
22.23
- Max
- 74.32
- Q3
- 36.91
- META
- 22.23
- Median
- 20.53
- Q1
- 11.74
- Min
- 1.83
P/S Ratio (TTM)
Eli Lilly (LLY) at 13.27 is priced about in line with its industry on P/S ratio, while Meta Platforms (META) at 6.61 sits in the pricier quartile — META costs more per dollar of sales.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.27
- Max
- 70.39
- Q3
- 30.57
- LLY
- 13.27
- Median
- 7.62
- Q1
- 3.50
- Min
- 0.01
META
Media & Entertainment industry group
6.61
- Max
- 6.92
- META
- 6.61
- Q3
- 3.80
- Median
- 1.58
- Q1
- 0.67
- Min
- 0.00
P/B Ratio (MRQ)
Both look rich against book: Meta Platforms (META) at 6.17 sits in the upper P/B ratio quartile, and Eli Lilly (LLY) at 33.96 prices even higher, above its industry range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.96
- LLY
- 33.96
- Max
- 17.22
- Q3
- 8.05
- Median
- 3.87
- Q1
- 1.75
- Min
- -7.69
META
Media & Entertainment industry group
6.17
- Max
- 13.02
- META
- 6.17
- Q3
- 5.78
- Median
- 2.08
- Q1
- 0.83
- Min
- -5.00
Valuation Metrics
| Metric | LLY | META |
|---|---|---|
| P/E Ratio (TTM) | 40.00 | 22.23 |
| P/S Ratio (TTM) | 13.27 | 6.61 |
| P/B Ratio (MRQ) | 33.96 | 6.17 |
| Free Cash Flow Yield (TTM) | 1.05% | 1.43% |